Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is to target the pHLA complex mimicking TCR recognition. In this webinar, Dr. W. Frank […]
Read more
Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo
Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Corp Therapeutics targeting the immune system for oncology applications (such as immune checkpoint inhibitors, or ICIs) can in some cases lead to adverse effects in patients, and may affect multiple organ systems and/or cause CRS (cytokine release syndrome). Thus, predicting the safety and […]
Read more
Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform
Speaker: Yanan Guo, Ph.D. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation and novel GPCR-targeting antibody screening has posed significant challenges […]
Read more
Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. […]
Read more
Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice
Speaker: Li Hui, MD, PhD. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Therapeutic development of antibodies and antibody-based drugs is a multi-year process that involves high cost and significant risk. In recent years, a common discovery approach to ensure the quality of new anti-human therapeutic antibodies is to express select human immunoglobulin genes in […]
Read more
Joint, Lung, and Urinary Disease Models Offered at Biocytogen
Speaker: Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Inflammatory disease models are important preclinical research tools to study disease pathogenesis and uncover novel treatments. To directly evaluate the efficacy and safety of therapeutic drug candidates targeting these disorders, we can establish disease in wild-type and/or humanized mouse models. In this webinar, […]
Read moreWebinar Categories
- Antibody Discovery
- Humanized Animal Models
- Others
